The chief executive of Sareum, the AIM-listed structure-based drug discovery business, has revealed that the company would entertain a sale if it received offers of between £40m and £50m. Sareum's market capitalisation currently stands at £9.43m, but CEO Tim Mitchell defended the high asking price, saying that a significant amount of the company's value is set to be realised within the next twelve months. German drug discovery firm Evotec has been tipped as a potential buyer.